Posts tagged TRPV6 calcium channel
Soricimed to present four posters at AACR

Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20.

The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel.

Read More
Soricimed posts positive SOR-C13 data in solid tumors

Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers.

The primary goal of the study was to assess safety and tolerability of SOR-C13 in subjects with advanced carcinomas commonly known to express the TRPV6 channel and who had failed all previous anti-cancer treatments.  SOR-C13 is the first drug candidate targeting TRPV6 to enter human clinical trials.

Read More